Corcept achieved record Q4 revenue of $202.1 million, an 11% increase year-over-year, driven by strong demand in its Cushing’s syndrome business. While net income decreased due to higher operating expenses and a transition to a new specialty pharmacy vendor, the company ended the year with a strong cash position and set ambitious 2026 revenue guidance.

Corcept Therapeutics delivered revenue growth in Q3 2025 but experienced a substantial decline in net income and EPS due to increased R&D and SG&A spending. The company remains confident in its long-term growth, supported by a robust pipeline and expanded oncology programs.

Corcept Therapeutics experienced robust growth in its hypercortisolism business, achieving record numbers of new prescribers and patients. Despite this, financial results were impacted by a specialty pharmacy vendor's capacity issues. The company reported increased revenue year-over-year but a slight decline in net income and diluted EPS. Corcept also provided an updated revenue guidance for 2025.

Corcept Therapeutics reported revenue of $157.2 million for the first quarter of 2025, an increase from $146.8 million in the same period last year. Despite a decrease in net income and diluted EPS compared to the prior year, the company reiterated its full-year 2025 revenue guidance of $900 - $950 million.

Corcept Therapeutics posted Q4 2024 revenue of $181.9 million, a 34% increase year-over-year. However, net income slightly declined to $30.7 million, driven by higher research and development (R&D) expenses. The company remains financially strong with $603.2 million in cash and investments, supporting ongoing clinical programs. Corcept continues to advance its cortisol modulation therapies, with an NDA submitted for relacorilant and promising oncology and metabolic trials underway.

Corcept Therapeutics reported strong third-quarter results, with revenue reaching $182.5 million, a 48% increase compared to the third quarter of 2023. The company's net income was $47.2 million, or $0.41 per share (diluted). They also increased their 2024 revenue guidance to $675 - $700 million and are on track to submit an NDA for relacorilant.

Corcept Therapeutics reported a strong second quarter with revenue of $163.8 million, a 39% increase compared to the same period in 2023. The company also increased its 2024 revenue guidance to $640 - $670 million. Net income was $35.5 million, resulting in diluted earnings per share of $0.32.

Corcept Therapeutics announced first quarter financial results with revenue of $146.8 million, a 39% increase over the same period in 2023. The company increased its 2024 revenue guidance to $620 - $650 million.

Corcept Therapeutics announced its Q4 2023 financial results, featuring a 31% increase in revenue compared to Q4 2022, and a notable rise in net income. The company reiterated its 2024 revenue guidance, reflecting confidence in continued growth and market trends.

Corcept Therapeutics reported a 22% increase in revenue to $123.6 million for the third quarter of 2023, compared to $101.7 million in the same period last year. Net income was $31.4 million, with diluted earnings per share of $0.28. The company raised its 2023 revenue guidance to $470 - $480 million.

Corcept Therapeutics announced positive results for the second quarter of 2023, with revenue reaching $117.7 million, a 14% increase compared to the same period in 2022. The company's net income was $27.5 million, and it raised its 2023 revenue guidance to $455 - $470 million. The company is actively advancing its clinical development programs, including studies for Cushing's syndrome, ovarian cancer, ALS, and NASH.

Corcept Therapeutics reported Q1 2023 revenue of $105.7 million, compared to $93.7 million in Q1 2022. Net income was $15.9 million, or $0.14 per share diluted, compared to $22.8 million, or $0.20 per share diluted, in the same period last year. The company raised its 2023 revenue guidance to $435 - $455 million.

Corcept Therapeutics reported Q4 2022 revenue of $103.1 million, compared to $98.8 million in Q4 2021. Net income for Q4 2022 was $16.6 million, compared to $32.1 million in Q4 2021. The company provided 2023 revenue guidance of $430 - $450 million.

Corcept Therapeutics reported revenue of $101.7 million for the third quarter of 2022, compared to $96.1 million in the third quarter of 2021. Net income was $34.6 million, compared to $30.5 million in the third quarter of 2021.

Corcept Therapeutics reported Q2 2022 revenue of $103.4 million, a net income of $27.4 million, and a diluted net income per common share of $0.24. The company reiterated its 2022 revenue guidance of $400 - $430 million. Cash and investments increased to $382.0 million.

Corcept Therapeutics reported a revenue of $93.7 million for the first quarter of 2022, compared to $79.4 million in the first quarter of 2021. Diluted net income per share was $0.20, compared to $0.18 in the first quarter of 2021. The company reiterated its 2022 revenue guidance of $400 – $430 million.

Corcept Therapeutics reported Q4 2021 revenue of $98.8 million, compared to $85.7 million in Q4 2020. GAAP net income was $32.1 million, compared to $26.0 million in the same quarter of the previous year. The company anticipates 2022 revenue of $400 – $430 million.

Corcept Therapeutics reported a strong third quarter with revenue of $96.1 million, an 11% increase from Q3 2020. GAAP diluted net income was $0.24 per share, and non-GAAP diluted net income was $0.30 per share. The company tightened its 2021 revenue guidance to $365 - $375 million.

Corcept Therapeutics reported a revenue of $91.6 million for Q2 2021, compared to $88.6 million in Q2 2020. GAAP diluted net income was $0.21 per share, and non-GAAP diluted net income was $0.30 per share. The company reiterated its 2021 revenue guidance of $355 – $385 million.

Corcept Therapeutics reported a revenue of $79.4 million for Q1 2021, compared to $93.2 million in Q1 2020. GAAP net income was $23.5 million, or $0.18 per share, compared to $30.1 million, or $0.25 per share, in the same quarter of the previous year. Non-GAAP net income was $25.8 million, or $0.20 per share, compared to $41.2 million, or $0.34 per share, in the first quarter of 2020.

Corcept Therapeutics announced its Q4 and full-year 2020 financial results, with Q4 revenue at $85.7 million and GAAP net income at $26.0 million. The company's cash and investments increased to $476.9 million, and it reiterated its 2021 revenue guidance of $375 - 405 million.

Corcept Therapeutics reported a 6% increase in revenue compared to Q3 2019, with revenue reaching $86.3 million. The company's GAAP net income was $21.6 million, and non-GAAP net income was $30.0 million. They narrowed their 2020 revenue guidance to $355 - $365 million and announced a $200 million stock repurchase program.

Corcept Therapeutics reported a revenue of $88.6 million for the second quarter of 2020, a 23% increase compared to the same period in 2019. The company's GAAP diluted net income per share was $0.23, and non-GAAP diluted net income per share was $0.32. They reaffirmed their 2020 revenue guidance of $355 – 375 million.

Corcept Therapeutics reported a strong first quarter with revenue of $93.2 million, a 44% increase from Q1 2019. GAAP diluted net income was $0.25 per share, and non-GAAP diluted net income was $0.34 per share. The company reaffirmed its 2020 revenue guidance of $355 — 375 million.

Corcept Therapeutics reported a 32% increase in fourth-quarter revenue, reaching $87.9 million, and a GAAP net income of $29.4 million, or $0.24 per share. The company's cash and investments increased to $315.3 million. They reiterated their 2020 revenue guidance of $355 - $375 million and are advancing their portfolio of selective cortisol modulators through various clinical trials.